- Funded through Novo Seeds’ company creation and building efforts
- Focus on rare underserved bleeding disorders with large unmet need
- Brings together a strong industrial R&D team with deep expertise in hemophilia and clinically validated technologies from Novo Nordisk and Genmab A/S
Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today that it has invested in a new portfolio company Hemab ApS (Hemab), which is focused on the development of bispecific antibodies for the treatment of rare bleeding disorders.
